Houston, TX, (September 14, 2004) Cytogenix, Inc. (CYGX: OTC: BB)
CytoGenix, Inc. (CYGX: OTC: BB) announces that Kurt L. Berens has agreed to join the company as Vice President of Product Development. Formerly a Section Manager for Wyle Laboratories, Cellular and Biomedical Group at NASA-Johnson Space Center, Houston, Berens has over fifteen years of clinical research experience.
Dr. Malcolm Skolnick, CytoGenix CEO, states, "Kurt is an excellent clinical scientist with experience in drug development and successes in the FDA drug approval process. Because of the promise of our technology, CytoGenix continues to attract outstanding professionals. Our discovery programs will continue to yield a flow of new products to complement our two lead drug candidates. From these efforts, we plan to submit several IND applications in the upcoming months."
Prior to his work at NASA, Berens was Senior Project Manager for Clinical Development and Regulatory Affairs at Texas Biotechnology Corp. of Houston, Texas where he was responsible for managing successful clinical trials of the company's lead drug. He has authored or co-authored twenty scientific published papers and two book chapters. He has been an Instructor of Bio-pharmaceutics and Pharmacokinetics at University of Houston, College of Pharmacy and an Instructor of Pharmacotherapeutics in Space Medicine at the University of Texas Medical Branch Galveston.
CytoGenix, Inc. is a biopharmaceutical company that develops and markets innovative products and services based on its proprietary DNA expression technology. CytoGenix has products in pre-clinical development including, anti-herpes, anti-psoriasis and anti-inflammatory topical creams. The company owns a US patent for its core DNA expression technology and has 40 international or US pending patent applications.
SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.
Contact: Communications Director — Juan Ferreira, (407) 774-9949
